Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Fradet

Showing results (71-80 of 110) with videos related to

Pageof 11
Sort By:
International Journal of Cancer|March 17, 2000
Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypesC Pfister, H Larue, L Moore, et al.
American Journal of Clinical Oncology|January 1, 1988
Total androgen blockade for metastatic cancer of the prostateG Béland, M Elhilali, Y Fradet, et al.
The Journal of Urology|May 1, 1997
Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumorsM Grégoire, Y Fradet, F Meyer, et al.
Progress in Clinical and Biological Research|January 1, 1987
Total androgen blockade vs orchiectomy in stage D2 prostate cancerG Béland, M Elhilali, Y Fradet, et al.
Human Pathology|November 26, 1999
Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumorsC Pfister, L Lacombe, M C Vezina, et al.
The Journal of Urology|February 25, 2000
Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysisR K Nam, D A Redelmeier, P E Spiess, et al.
Cancer|October 15, 1993
Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cellsR B Bonner, G P Hemstreet, Y Fradet, et al.
Urology|April 10, 1999
CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology GroupL H Klotz, S L Goldenberg, M Jewett, et al.
Carcinogenesis|December 23, 1999
P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokersH LaRue, P Allard, M Simoneau, et al.
The Journal of Urology|August 13, 2003
Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomyL H Klotz, S L Goldenberg, M A Jewett, et al.
Pageof 11

Showing results (71-80 of 110) with videos related to

Sort By:
Pageof 11
International Journal of Cancer|March 17, 2000
Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypesC Pfister, H Larue, L Moore, et al.
American Journal of Clinical Oncology|January 1, 1988
Total androgen blockade for metastatic cancer of the prostateG Béland, M Elhilali, Y Fradet, et al.
The Journal of Urology|May 1, 1997
Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumorsM Grégoire, Y Fradet, F Meyer, et al.
Progress in Clinical and Biological Research|January 1, 1987
Total androgen blockade vs orchiectomy in stage D2 prostate cancerG Béland, M Elhilali, Y Fradet, et al.
Human Pathology|November 26, 1999
Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumorsC Pfister, L Lacombe, M C Vezina, et al.
The Journal of Urology|February 25, 2000
Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysisR K Nam, D A Redelmeier, P E Spiess, et al.
Cancer|October 15, 1993
Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cellsR B Bonner, G P Hemstreet, Y Fradet, et al.
Urology|April 10, 1999
CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology GroupL H Klotz, S L Goldenberg, M Jewett, et al.
Carcinogenesis|December 23, 1999
P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokersH LaRue, P Allard, M Simoneau, et al.
The Journal of Urology|August 13, 2003
Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomyL H Klotz, S L Goldenberg, M A Jewett, et al.
Pageof 11